- ICH GCP
- EU-register voor klinische proeven
Laatste proeven
EudraCT Number: 2006-004084-66 | Sponsor Protocol Number: om 112 | Start Date: 2002-07-09 | |||||||||||
Sponsor Name: OSPEDALE ONCOLOGICO DI BARI | |||||||||||||
Full Title: A phase II study on the efficacy and safety of topotecan in the treatment of patients with brain metastases | |||||||||||||
Medical condition: Brain metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002385-11 | Sponsor Protocol Number: BIG01−01/BO16348B | Start Date: 2002-05-16 | |||||||||||
Sponsor Name: F. HOFFMANN - LA ROCHE LTD. | |||||||||||||
Full Title: - | |||||||||||||
Medical condition: - | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005127-29 | Sponsor Protocol Number: TAX_GMA_302 | Start Date: 2001-05-21 | |||||||||||
Sponsor Name: SANOFI-AVENTIS | |||||||||||||
Full Title: MULTICENTER PHASE III RANDOMIZED TRIAL COMPARING DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL (AC->T) WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE FOLLOWED BY DOCETAXEL AND TRASTUZUMAB (HERCEPTI... | |||||||||||||
Medical condition: node positive and high risk node negative patients with operable breast cancer containing the the HER2 alteration. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: HU (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000238-36 | Sponsor Protocol Number: IST-399 | Start Date: 1999-10-05 | |||||||||||
Sponsor Name: The University of Edinburgh & Lothian Health Board | |||||||||||||
Full Title: Third International Stroke Trial (IST-3) of thrombolysis for acute ischaemic stroke | |||||||||||||
Medical condition: Acute ischaemic stroke refers to strokes caused by thrombosis or embolism and accounts for 85% of all strokes. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-018118-21 | Sponsor Protocol Number: OXN2503 | Start Date: | |||||||||||
Sponsor Name: Mundipharma Research GmbH & Co. KG | |||||||||||||
Full Title: An exploratory, randomised, double-blind, placebo-controlled, parallel group, pilot study to assess the analgesic efficacy of oxycodone/naloxone prolonged release tablets (OXN PR) compared to place... | |||||||||||||
Medical condition: Bladder Pain Syndrome (BPS), formerly addressed as IC/PBS (interstitial cystitis /Painful Bladder Syndrome) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) CZ (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003673-10 | Sponsor Protocol Number: AV003 | Start Date: | ||||||||||||||||
Sponsor Name: Bond Avillion 2 Development LP | ||||||||||||||||||
Full Title: A Long-term, Randomized, Double-blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as Needed in Response to Symptoms in S... | ||||||||||||||||||
Medical condition: Moderate to severe asthma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) SK (Completed) ES (Completed) IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002951-39 | Sponsor Protocol Number: CAAA601A32201 | Start Date: | |||||||||||||||||||||||||||||||
Sponsor Name: Advanced Accelerator Applications SA | |||||||||||||||||||||||||||||||||
Full Title: A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheoc... | |||||||||||||||||||||||||||||||||
Medical condition: somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||
Trial protocol: SE (Prematurely Ended) FR (Ongoing) PT (Ongoing) PL (Ongoing) BE (Completed) IT (Ongoing) NL (Ongoing) | |||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005325-67 | Sponsor Protocol Number: 1239102 | Start Date: | |||||||||||
Sponsor Name: Centre Hospitalier de Toulouse | |||||||||||||
Full Title: Evaluation of tolerance, suckling and food intake after repeated nasals administrations of Oxytocin in PWS infants | |||||||||||||
Medical condition: Prader Willi Syndrom | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000540-18 | Sponsor Protocol Number: VX16-661-114 | Start Date: | |||||||||||
Sponsor Name: Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: Phase 3b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Safety, Efficacy, and Tolerability of Tezacaftor/Ivacaftor (TEZ/IVA) in an Orkambi-experienced Population ... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004057-23 | Sponsor Protocol Number: 2021-12945 | Start Date: | ||||||
Sponsor Name: Radboudumc | ||||||||
Full Title: Ethanol submandibular duct ligation for drooling in children with neurodisabilities | ||||||||
Medical condition: Drooling or sialorrhea | ||||||||
|
||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | |||||||
Trial protocol: NL (Ongoing) | ||||||||
Trial results: (No results available) |